◎ Sugi Atlas

Atlas / Drug / Acetylcysteine

Acetylcysteine

drug
On this page

Also known as A-cysAcc-600AcetadoteAcetilcisteinaAcetyl cysteineAirbronBroncholysinCetylevEn-cysFabrolFluimicilFluimucetinFluimucilFluimucil 600Fluimucil longFluimucil nIlubeMercapturic acidMucomyst

Summary

Acetylcysteine (CHEMBL600) is an approved small-molecule antiinfective agent (ATC R05CB01); indicated across 129 conditions including drug-induced liver injury and injury.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: R05CB01 (+2 more)
  • Indications: 129 conditions
  • Clinical trials: 389
  • Chemistry: 163.2 Da · C5H9NO3S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL600
NameAcetylcysteine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID12035
ChEBICHEBI:28939
ATCR05CB01, S01XA08, V03AB23
Molecular formulaC5H9NO3S
Molecular weight163.2
InChIKeyPWKSKIMOESPYIA-BYPYZUCNSA-N

SMILES: CC(=O)N[C@@H](CS)C(=O)O

IUPAC name: (2R)-2-acetamido-3-sulfanylpropanoic acid

ChEBI definition: An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.

Pharmacological roles (ChEBI): antiinfective agent, antioxidant, antiviral drug, antidote to paracetamol poisoning, vulnerary, mucolytic, radical scavenger, ferroptosis inhibitor, geroprotector.

Other ChEBI roles (chemical / environmental): human metabolite.

Also known as: A-cys, Acc-600, Acetadote, Acetilcisteina, Acetyl cysteine, Acetylcysteine, Airbron, Broncholysin, Cetylev, En-cys, Fabrol, Fluimicil

Parent form; salt/anhydrous children: CHEMBL6068327

Patent coverage: 28,636 distinct patent families (95,016 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Survival motor neuron protein, ATP-dependent DNA helicase Q1, RecQ-like DNA helicase BLM, 4’-phosphopantetheinyl transferase ffp, Thrombopoietin, Thyroid hormone receptor beta, Prostaglandin G/H synthase 2, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 17 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ALOX157.6Potency25.1nMCHEMBL_ACT_4465698
THRB6.25Potency562.3nMCHEMBL_ACT_3996999
Q639216.05AC50890nMCHEMBL_ACT_25173954
BLM6Potency1000nMCHEMBL_ACT_4741981
BLM6Potency1000nMCHEMBL_ACT_4913872
RECQL5.85Potency1412nMCHEMBL_ACT_4723571
SMN15.8Potency1585nMCHEMBL_ACT_3880306
PTGS25.62AC502400nMCHEMBL_ACT_25165756
NFKB15.35Potency4467nMCHEMBL_ACT_3672661
NFKB15.35Potency4467nMCHEMBL_ACT_4585397

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

129 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
drug-induced liver injury4MONDO:0005359EFO:0004228
injury4MONDO:0021178EFO:0000546
eye disorder4MONDO:0005328EFO:0003966
cystic fibrosis4MONDO:0009061MONDO:0009061
common cold3MONDO:0005709EFO:0007214
chronic kidney disease3MONDO:0005300EFO:0003884
idiopathic pulmonary fibrosis3MONDO:0800504EFO:0000768
myocardial infarction3MONDO:0005068EFO:0000612
alcoholic hepatitis3MONDO:0001505EFO:1001345
ischemia reperfusion injury3MONDO:0005203EFO:0002687
atrial fibrillation3MONDO:0004981EFO:0000275
infertility disorder3MONDO:0005047EFO:0000545
bulimia nervosa3MONDO:0005452EFO:0005204
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
respiratory system disorder3MONDO:0005087EFO:0000684
cannabis dependence3MONDO:0005689EFO:0007191
sinusitis3MONDO:0005961EFO:0007486
female infertility3MONDO:0021124EFO:0008560
pulmonary fibrosis3MONDO:0002771EFO:0009448
acute kidney injury3MONDO:0002492MONDO:0002492
coronary artery disorder3MONDO:0005010EFO:0001645
mucositis3MONDO:0020579EFO:1001898
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
acute myocardial infarction3MONDO:0004781EFO:0008583
graft versus host disease3MONDO:0013730MONDO:0013730
hematologic disorder3MONDO:0005570HP:0001871
sickle cell disease3MONDO:0011382MONDO:0011382
retinitis pigmentosa3MONDO:0019200MONDO:0019200
psychotic disorder3MONDO:0005485EFO:0005407
influenza3MONDO:0005812EFO:0007328
psoriasis3MONDO:0005083EFO:1001494
thrombotic disease3MONDO:0000831MONDO:0000831
age-related macular degeneration3MONDO:0005150EFO:0001365
acute liver failure3MONDO:0019542MONDO:0019542
hearing loss disorder2MONDO:0005365EFO:0004238
dry eye syndrome2MONDO:0006733EFO:1000906
melanoma2MONDO:0005105EFO:0000756
kidney disorder2MONDO:0005240EFO:0003086
polycystic ovary syndrome2MONDO:0008487EFO:0000660
post-traumatic stress disorder2MONDO:0005146EFO:0001358
autism2MONDO:0005260EFO:0003758
nicotine dependence2MONDO:0008575EFO:0003768
obsessive-compulsive disorder2MONDO:0008114EFO:0004242
acute lung injury2MONDO:0015796EFO:0004610
Tourette syndrome2MONDO:0007661EFO:0004895
neuralgia2MONDO:0021667EFO:0005762
mental disorder2MONDO:0005084EFO:0000677
cocaine dependence2MONDO:0005186EFO:0002610
pyelonephritis2MONDO:0006939EFO:1001141
methamphetamine dependence2MONDO:0005419EFO:0004701
autoimmune thrombocytopenic purpura2MONDO:0008558EFO:0007160
cutaneous melanoma2MONDO:0005012EFO:0000389
diffuse scleroderma2MONDO:0005019EFO:0000404
bacterial infectious disease with sepsis2MONDO:0005229EFO:0003033
autism spectrum disorder2MONDO:0005258EFO:0003756
myopathy2MONDO:0005336EFO:0004145
chronic bronchitis2MONDO:0005607EFO:0006505
thrombocytopenia2MONDO:0002049HP:0001873
Gaucher disease2MONDO:0018150Orphanet:77259
ST-elevation myocardial infarction2MONDO:0041656EFO:0008585
transposition of the great arteries2MONDO:0000153MONDO:0000153
homocystinuria2MONDO:0004737MONDO:0004737
brain injury2MONDO:0043510MONDO:0043510
hepatic veno-occlusive disease2MONDO:0019514MONDO:0019514
Fuchs’ endothelial dystrophy2MONDO:0005321Orphanet:98974
stroke disorder2MONDO:0005098EFO:0000712
epilepsy2MONDO:0005027EFO:0000474
chronic progressive multiple sclerosis2MONDO:0005284EFO:0003840
bipolar disorder2MONDO:0004985EFO:0009963
Parkinson disease2MONDO:0005180MONDO:0005180
multiple sclerosis2MONDO:0005301MONDO:0005301
alcohol abuse2MONDO:0002046MONDO:0007079
biliary atresia2MONDO:0008867MONDO:0008867
adrenoleukodystrophy2MONDO:0018544MONDO:0015339
tuberculosis2MONDO:0018076MONDO:0018076
neurofibromatosis type 12MONDO:0018975MONDO:0018975
Huntington disease2MONDO:0007739MONDO:0007739
systemic lupus erythematosus2MONDO:0007915MONDO:0007915
acute myeloid leukemia2MONDO:0018874EFO:0000222
uterine corpus leiomyoma2MONDO:0007886EFO:0000731
stomatitis2MONDO:0004842EFO:1001904
trichotillomania2MONDO:0013189MONDO:0013189
hypertrophic cardiomyopathy1MONDO:0005045EFO:0000538
altitude sickness1MONDO:0006625EFO:1000782
pathological gambling1MONDO:0011662EFO:0004699
noise induced hearing loss1MONDO:0013098EFO:1001254
neuromuscular disease1MONDO:0019056EFO:1001902
kidney failure1MONDO:0001106EFO:1002048
substance-related disorder1MONDO:0002494MONDO:0002491
breast neoplasm1MONDO:0021100MONDO:0007254
irritable bowel syndrome1MONDO:0005052EFO:0000555
fibromyalgia1MONDO:0005546EFO:0005687
respiratory tract infectious disorder1MONDO:0024355MONDO:0024355
essential thrombocythemia1MONDO:0005029EFO:0000479
lymphoma1MONDO:0005062EFO:0000574
acquired polycythemia vera1MONDO:0009891EFO:0002429
pseudomyxoma peritonei1MONDO:0017048EFO:0007456
beta thalassemia1MONDO:0019402MONDO:0016486
Niemann-Pick disease type C1MONDO:0018982MONDO:0018982
primary myelofibrosis1MONDO:0009692MONDO:0044903
inborn mitochondrial metabolism disorder1MONDO:0004069MONDO:0044970
pancreatitis1MONDO:0004982EFO:0000278
HIV infectious disease1MONDO:0005109EFO:0000764
cystinosis1MONDO:0016239MONDO:0016239
acute respiratory distress syndrome0MONDO:0006502EFO:1000637
major depressive disorder0MONDO:0002009MONDO:0002009
thrombotic thrombocytopenic purpura0MONDO:0018896MONDO:0018896
depressive disorder0MONDO:0002050MONDO:0002050
persian gulf syndrome0MONDO:0005907EFO:0007430
Alzheimer disease0MONDO:0004975MONDO:0004975
type 2 diabetes mellitus0MONDO:0005148MONDO:0005148
metabolic dysfunction-associated steatotic liver disease0MONDO:0013209EFO:0003095

17 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 389.

Phase distribution

PhaseTrials
PHASE2104
Not specified70
PHASE465
PHASE351
PHASE132
PHASE1/PHASE227
PHASE2/PHASE320
EARLY_PHASE120

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03652753PHASE4RECRUITINGPilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)
NCT04460521PHASE4RECRUITINGThe ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome
NCT05408247PHASE4RECRUITINGA Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder
NCT06546475PHASE4NOT_YET_RECRUITINGA Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine
NCT06956157PHASE4ACTIVE_NOT_RECRUITINGNAC for Treatment-Resistant OCD and Other Related Disorders
NCT07409727PHASE4RECRUITINGEffect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill Mechanically Ventilated Patients
NCT00184977PHASE4COMPLETEDCOPD on Primary Care Treatment (COOPT)
NCT00188773PHASE4COMPLETEDMechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion
NCT00190034PHASE4SUSPENDEDAcetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.
NCT00247507PHASE4UNKNOWNThe Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
NCT00356954PHASE4COMPLETEDNASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization
NCT00492518PHASE4COMPLETEDAcetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy
NCT00512265PHASE4COMPLETEDInfluence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer
NCT00525551PHASE4COMPLETEDEfficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis
NCT00558142PHASE4COMPLETEDMechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
NCT00569465PHASE4TERMINATEDN-Acetylcysteine and Arginine Administration in Diabetic Patients
NCT00716001PHASE4UNKNOWNEffect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure
NCT00866866PHASE4UNKNOWNThe Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms
NCT00896025PHASE4TERMINATEDStudy of N-Acetylcysteine in Acute Liver Failure (ALF)
NCT00969904PHASE4COMPLETEDPilot Study to Assess the Effect of High Dose N-acetylcysteine (NAC) in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00996424PHASE4TERMINATEDThe Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function
NCT01021163PHASE4COMPLETEDEffects of N-acetylcysteine on Pulmonary Function in High-risk Patients Undergoing Off-pump Coronary Bypass Surgery
NCT01050270PHASE4COMPLETEDScottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning Study (SNAP)
NCT01111422PHASE4UNKNOWNAnti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients
NCT01223326PHASE4COMPLETEDN-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection
NCT01339858PHASE4COMPLETEDThe Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
NCT01394419PHASE4COMPLETEDEffect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft
NCT01501110PHASE4COMPLETEDEffects of N-acetylcysteine on Low T3 Syndrome
NCT01653171PHASE4COMPLETEDPremedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy
NCT01841411PHASE4UNKNOWNRole of N-Acetylcysteine in Treatment of Bacterial Vaginosis
NCT02168387PHASE4COMPLETEDEfficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient
NCT02239107PHASE4COMPLETEDN-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome
NCT02241876PHASE4UNKNOWNTHE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS
NCT02249546PHASE4UNKNOWNEfficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection
NCT02252341PHASE4UNKNOWNEfficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder
NCT02357290PHASE4COMPLETEDOpen-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders
NCT02357303PHASE4COMPLETEDSimethicone and N-acetylcysteine in Upper Endoscopy - Prospective Double-blinded Randomized Controlled Trial
NCT02476526PHASE4COMPLETEDSafety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
NCT02505477PHASE4COMPLETEDTreatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine
NCT02579772PHASE4COMPLETEDEffects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 6 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 17

This page pulls from 17 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandhgncmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchemuniprot